Filings monitor · CRL

What CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s SEC filings said

10-Q for 2026Q3, filed 4 Nov 2026, and 2 8-Ks since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Net Income and Profitability83 · importance in its document · 8-K exhibit · 4 Nov 2026
   Third-quarter GAAP net income attributable to common shareholders was $333.1 million, or $6.86 per diluted share, compared with $54.4 million, or $1.10, in 2025. The year-over-year increase included a $245.6 million, or $5.06 per-share,…
2. Guidance and Outlook82 · importance in its document · 8-K exhibit · 4 Nov 2026
   On November 4, 2026, Charles River raised its 2026 organic revenue growth guidance to at least 1.5%, from a prior range of 0.0%–1.0%. It increased non-GAAP EPS guidance to $11.35–$11.55 from $11.15–$11.45, and GAAP EPS guidance to…
3. Income Tax Rate Changes72 · importance in its document · 10-Q · 2026Q3
   The effective tax rate was (96.0)% in the third quarter of 2026, compared with 36.3% in the third quarter of 2025, as the company recorded a $163.8 million tax benefit instead of $31.6 million of tax expense. A $201 million tax benefit…
4. Acquisition / Partnership / Divestiture71 · importance in its document · 8-K exhibit · 9 Nov 2026
   Charles River agreed to acquire Frontage Holdings’ bioanalysis and DMPK businesses in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million in contingent performance payments; closing is expected in the first…
5. Liquidity and Debt Position66 · importance in its document · 10-Q · 2026Q3
   Cash and cash equivalents totaled $200.4 million at September 26, 2026, down from $213.8 million at December 27, 2025; $195.8 million was held in non-U.S. entities. Total debt outstanding increased to $2.443 billion from $2.117 billion,…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 4 Nov 2026

Full report · Filing on EDGAR

• Income Tax Rate ChangesImportance 72
  The effective tax rate was (96.0)% in the third quarter of 2026, compared with 36.3% in the third quarter of 2025, as the company recorded a $163.8 million tax benefit instead of $31.6 million of tax expense. A $201…
• Liquidity and Debt PositionImportance 66
  Cash and cash equivalents totaled $200.4 million at September 26, 2026, down from $213.8 million at December 27, 2025; $195.8 million was held in non-U.S. entities. Total debt outstanding increased to $2.443 billion…
• Acquisition / Partnership / DivestitureImportance 65
  The company acquired an additional 79% interest in PathoQuest SAS on April 17, 2026, for $67.4 million, and acquired Cambodian NHP Supplier assets on January 14, 2026, for a preliminary purchase price of $507.3…
• Capital Return ProgramImportance 64
  The October 29, 2025 stock repurchase authorization permits up to $1.0 billion of buybacks. During the nine months ended September 26, 2026, the company repurchased 1.7 million shares for $300.0 million under the…
• Headcount and RestructuringImportance 62
  The Create the Future program combines workforce optimization, real-estate rationalization, procurement synergies, global business service expansion, process improvements, and AI-enabled automation. The company expects…
• Operating Margin DriversImportance 60
  Consolidated operating income increased 43.4% to $442.4 million for the nine months ended September 26, 2026, and operating margin rose 460 basis points to 14.8%. Manufacturing operating income rose $132.9 million to…
• Market Demand TrendsImportance 49 · +2 more on this subject
  Charles River reported an improving client spending environment, principally in Discovery and Safety Assessment (DSA), as biotech funding increased and global biopharmaceutical companies refocused investment on…
• FX / Currency ImpactImportance 49
  The company operates globally, with the Euro, Canadian Dollar, and British Pound among the principal functional currencies of its foreign subsidiaries; translation adjustments also reflected the Mauritian Rupee,…
• Operating Expense TrendsImportance 46
  Unallocated corporate costs increased $73.2 million, or 38.8%, to $261.8 million for the nine months ended September 26, 2026, and rose to 8.8% of revenue from 6.2%. The increase primarily reflected higher acquisition,…
• Strategic Cost ReductionImportance 40
  In the third quarter of fiscal 2026, the company announced Create the Future, a unified framework expanding its transformation and efficiency initiatives. The program includes process improvements, procurement…
• Interest Rate and Refinancing ExposureImportance 37
  At September 26, 2026, the company had $943.2 million outstanding under its revolving facility and $1.5 billion in Senior Notes, for total debt of $2.443 billion. The $2.0 billion multi-currency Credit Facility matures…
• Revenue Performance and MixImportance 31
  Revenue for the nine months ended September 26, 2026 decreased 1.3% to $2,982.6 million from $3,021.2 million, while third-quarter revenue fell 2.2% to $982.7 million. Nine-month service revenue declined 2.5% to…

8-K filings last 12 months

• Press release attached to an 8-K9 Nov 2026 · 8-K
  Read from the attached exhibit: Acquisition / Partnership / Divestiture · Clinical Bioanalysis Client Continuity · Bioanalysis Market Demand
• Guidance raised4 Nov 2026 · 8-K Item 2.02 · Flagged · rule score 60
  “Increases 2026 guidance for revenue and non-GAAP earnings per share.”
  Read from the attached exhibit: Net Income and Profitability · Guidance and Outlook · Operating Cash Flow Trends
• Press release attached to an 8-K24 Sept 2026 · 8-K
  Read from the attached exhibit: Operating Margin Drivers · Strategic Initiatives · Guidance and Outlook
• Results (release not read)5 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Guidance / Outlook · Income Tax Rate Changes · Acquisition / Partnership / Divestiture
• Management change (filing not read)11 May 2026 · 8-K Item 5.02 · Routine · rule score 20
• Results (release not read)7 May 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)18 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20
• Management change (filing not read)18 Feb 2026 · 8-K Item 5.02 · Routine · rule score 20
• Results (release not read)13 Jan 2026 · 8-K Item 2.02 · Routine · rule score 20
• Management change (filing not read)9 Jan 2026 · 8-K Item 5.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 5 Aug 2026
  Liquidity and Debt Position · Operating Expense Trends · Acquisitions and Divestitures

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.